ScholarIQanswers from OpenAlex & ORCID
Brian Lestini
ResearcherPublications, citations & collaboration network
Brian Lestini is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Brian Lestini have?
ScholarIQindexed works
Brian Lestini has 82 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Brian Lestini have?
ScholarIQcitation count
Brian Lestini has 13,169 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Brian Lestini?
ScholarIQh-index
Brian Lestini has an h-index of 19 in OpenAlex.
What is the i10-index of Brian Lestini?
ScholarIQi10-index
Brian Lestini has an i10-index of 22 in OpenAlex.
What is the OpenAlex record for Brian Lestini?
ScholarIQopenalex
The OpenAlex for Brian Lestini is on the source record.
What are the most-cited papers on Brian Lestini?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su, Amaya Virós, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis‐Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew J. Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noé, Maryou Lambros, Felipe C. Geyer, Nathalie Dhomen, Ion Niculescu‐Duvaz, Alfonso Zambon, Dan Niculescu‐Duvaz, Natasha Preece, Lídia Robert, Nicholas Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, K. B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, René González, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas, Richard Marais
Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists
Brian Lestini, Kelly C. Goldsmith, Mark Fluchel, Xueyuan Liu, Niel Chen, Bella Goyal, Bruce Pawel, Michael D. Hogarty